MARKET

NVS

NVS

Novartis
NYSE
76.01
-1.13
-1.46%
After Hours: 76.01 0 0.00% 16:11 09/23 EDT
OPEN
76.32
PREV CLOSE
77.14
HIGH
76.62
LOW
75.53
VOLUME
2.74M
TURNOVER
0
52 WEEK HIGH
94.26
52 WEEK LOW
75.53
MARKET CAP
165.91B
P/E (TTM)
7.45
1D
5D
1M
3M
1Y
5Y
Novartis (NVS) to Focus on US Markets Backed by 8 Key Drugs
Novartis (NVS) unveils a new focused strategy with the spotlight on the US markets driven by eight key brands that are expected to have a multi-billion dollar peak sales potential.
Zacks · 2d ago
Citius Pharma Inks Clinical Collaboration For I/ONTAK Combo Regime in Solid Tumor Settings
Benzinga · 2d ago
Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..
Reuters
Benzinga · 3d ago
Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands
Benzinga · 3d ago
Novartis aims to focus on US market, eyes top-5 spot by 2027
Novartis (NYSE:NVS) <a href="https://www.novartis.com/news/media-releases/no...
Seekingalpha · 3d ago
Novartis Announced Focusing Strategy on Five Core Therapeutic Areas, Key Technology Platforms, and U.S.; Said Will Continue to Deliver Improved Financials With +4% Sales CAGR Through 2027 and Core Op Inc Margin ~40%+ in Mid-long Term
Novartis executives are meeting investors and industry analysts in Basel today, sharing insights into the updated company strategy at the annual Meet Novartis Management event.
Benzinga · 3d ago
UPDATE 3-Novartis to prioritise U.S. market, unfazed by drug pricing pushback
UPDATE 3-Novartis to prioritise U.S. market, unfazed by drug pricing pushback
Reuters · 3d ago
Novartis Says to Adopt 'US-First Mindset' to Become Top-Five Player by 2027
Novartis Says to Adopt 'US-First Mindset' to Become Top-Five Player by 2027
MT Newswires · 3d ago
More
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Webull offers kinds of Novartis AG (ADR) stock information, including NYSE:NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.